Search clinical trials for: Cardiovascular Diseases, ACZ885, impaired glucose tolerance, IGT, Canakinumab

Total 79545 results

Novartis Pharmaceuticals

Completed

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Diabetes Mellitus, Type 2 | Atherosclerosis | Prediabetic State

Germany, Israel, United States, Canada, United Kingdom
Novartis

Completed

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Cryopyrin-Associated Periodic Syndromes | Neonatal Onset Multisystem Inflammatory Disease | Muckle Wells Syndrome

United States, Germany, Italy, Spain, United Kingdom, Turkey, France, Belgium, India
Novartis Pharmaceuticals

Completed

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement (Behcet)

Behcet Disease

Turkey
Novartis Pharmaceuticals

Terminated

ACZ885 for the Treatment of Abdominal Aortic Aneurysm (AAA)

Abdominal Aortic Aneurysm (AAA)

Denmark, United States, Netherlands, Sweden, United Kingdom
Novartis Pharmaceuticals
International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Southwest...

Terminated

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 1)

Systemic Juvenile Idiopathic Arthritis

United States, Argentina, Canada, Switzerland, Germany, United Kingdom, Israel, South Africa, Belgium, Greece, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru, Denmark
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia (CAN-COVID)

Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Spain, United States, United Kingdom, Russian Federation, Italy, France
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Sickle Cell Anemia

Turkey, United States, Germany, Canada, United Kingdom, Israel, South Africa
Novartis Pharmaceuticals

No longer available

Canakinumab MAP in COVID-19 Pneumonia With CRS

Cytokine Release Syndrome in COVID-19-induced Pneumonia
Novartis Pharmaceuticals

Withdrawn

ACZ885 in Type 1 Diabetes Mellitus

Diabetes Mellitus | Diabetes Type 1

Germany, United Kingdom, United States, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).

TNF-receptor Associated Periodic Syndromes (TRAPS)

United Kingdom, Ireland, Italy
Novartis

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers

Healthy

Japan
Novartis

Completed

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Wet Age-Related Macular Degeneration

United Kingdom, Switzerland
M.D. Anderson Cancer Center

Recruiting

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Stage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditions

United States
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

Kawasaki Disease
Novartis

Completed

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation, Switzerland, Germany, United States, Belgium, Italy, Netherlands, Spain, Turkey
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)

Atherosclerosis

China, Germany, United States, Colombia, Romania, South Africa, Italy, Austria, Belgium, Croatia, Czechia, Estonia, Hungary, Japan, Russian Federation, Taiwan, Turkey, Netherlands, Australia, United Kingdom, Bulgaria, Greece, Slovenia, Norw... and more
Novartis Pharmaceuticals

Terminated

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

Peripheral Artery Disease

United States, Germany, Jordan
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

Germany, United States, Netherlands
Novartis

Completed

Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Arthritis, Juvenile Rheumatoid

Italy
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Adult Onset Still's Disease

Japan
Novartis Pharmaceuticals

Withdrawn

Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

Acute Gouty Arthritis
Novartis Pharmaceuticals

Terminated

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

Alzheimer Disease | Mild Cognitive Impairment

United States, Finland, United Kingdom, Iceland
Novartis Pharmaceuticals

Completed

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab (ß-SPECIFIC 4)

Systemic Juvenile Idiopathic Arthritis (SJIA)

Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Hereditary Periodic Fevers

Belgium, Italy, Japan, Russian Federation, Turkey, Spain, Germany, United Kingdom, France, United States, Ireland, Israel, Canada, Hungary, Netherlands, Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Myelodysplastic Syndromes

United States, Spain, Italy, Singapore, Korea, Republic of, Israel, Australia
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
Novartis

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Russian Federation, Germany, United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Systemic Juvenile Idiopathic Arthritis

Japan
Novartis

Completed

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome (REMITTER)

Muckle Wells Syndrome

United States, Spain, United Kingdom, France, Germany, India
Novartis Pharmaceuticals

Completed

Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms

NALP3 Mutation

United Kingdom, France, Germany, India, Spain
Novartis Pharmaceuticals

Terminated

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)

Non-Small Cell Lung Cancer

United States, Germany, Canada, France, Spain, Japan, Taiwan, Italy, Argentina, Austria, Poland, Russian Federation, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, Greece, Israel, Slovenia, Switzerland, ... and more
Novartis

Completed

Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation, Spain, Turkey, Switzerland
Novartis Pharmaceuticals

Completed

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Gouty Arthritis

Colombia, Spain, Taiwan, Russian Federation, Guatemala, Belgium, United States, Argentina, Czechia, Germany, Hungary, Poland, Portugal, Singapore, Slovakia, South Africa, Turkey, United Kingdom
Novartis

Completed

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

Arthritis, Gouty

United States, Switzerland, United Kingdom
Novartis

Completed

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Germany, Belgium, Spain, Austria, Canada
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Active, not recruiting

A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (CHORUS)

Non-small Cell Lung Cancer

United States
Novartis

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate

Rheumatoid Arthritis

Germany, Netherlands, Switzerland
Novartis Pharmaceuticals
PRINTO / PRCSG

Withdrawn

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 4Pa)

Systemic Juvenile Idiopathic Arthritis
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Triple Negative Breast Cancer (TNBC)

Netherlands, Spain, Hong Kong, Singapore, Italy, Australia, Israel, Japan, United States
Novartis Pharmaceuticals

Completed

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Dry Eye

United States
Novartis

Completed

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

Rheumatoid Arthritis

Spain, Germany, Belgium, Italy, Netherlands, United States
Novartis Pharmaceuticals

Terminated

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Polymyalgia Rheumatica | Inflammatory Diseases

Germany, Italy, United States, United Kingdom
Novartis

Terminated

Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Rheumatoid Arthritis

Germany, Belgium, Netherlands, Poland
Columbia University
Novartis

Recruiting

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1)

Carcinoma, Renal Cell

United States
Uma Borate

Recruiting

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Clonal Cytopenia of Undetermined Significance

United States
Novartis Pharmaceuticals

Terminated

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)

Non-Small-Cell Lung

Germany, Spain, Belgium, Canada, Netherlands, Italy, Taiwan, Argentina, Australia, Israel, Japan, Lebanon, France, Poland, United States, Jordan, Korea, Republic of, China, Brazil, Czechia, Greece, Russian Federation, Denmark, Hungary, ... and more
Novartis Pharmaceuticals

Terminated

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)

Non-small Cell Lung Cancer

Canada, Netherlands, Spain, France, Japan, Russian Federation, Germany, Belgium, Greece, Turkey, Taiwan, United States
Novartis

Completed

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Acute Gout

United States, Russian Federation, Switzerland, Germany, Turkey, Poland, Argentina, Canada, Belgium, France, United Kingdom

Search clinical trials for: Cardiovascular Diseases, ACZ885, impaired glucose tolerance, IGT, Canakinumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations